Welcome to SynAging SAS

Your R&D partner for in vitro and in vivo phenotypic models, accelerating drug discovery for proteopathic neurodegenerative diseases.

News

SynAging has a new official address and company identification number ! Please amend your records accordingly.

SynAging will be present at the following upcoming meetings:

Alzheimer's Association International Conference 2016 - Booth 825 & Posters
July 24. – 28. 2016, Toronto, Canada

3rd International Parkinson´s Disease Symposium 2016 - Booth & Posters
October 6 - 8, Luxembourg

BIO-Europe 2016 - through bioExpert
November 7. – 9, Cologne, Germany

Society for Neuroscience (SfN) 2016 - Posters
November 12. - 16, San Diego, USA

International Conference on Alzheimer's & Parkinson’s Diseases 2017 - Booth & Posters
March 29 . – April 2., Vienna, Austria

Press & Publications

Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X
Download PDF.pdf 1.3 MB

Servier publishes poster with SynAging data at SfN2015
Download PDF.pdf 1.5 MB

SynAging announces extension of its collaboration with Europe's largest biopharmaceutical company
Download PDF.pdf

First Commercial in vitro Test System for Human Neuroprotection in Proteopathic Diseases such as Alzheimer’s and Parkinson’s
Download PDF.pdf

SynAging Expands its Capabilities: Building a New Animal Facility and Hiring a Head of Pharmacology
Download PDF, 150 KB

Most recent SynAging’s article published with University Medicine Goettingen.
Download PDF, 1.1 MB

Poster ADPD 1: Download PDF, 2 MB

Poster ADPD 2: Download PDF, 2 MB

 

SynAging Provides Innovative Models for Neurodegenerative Diseases

Neurological diseases are among the most common threats to human health and difficult to treat. Millions of people are affected, especially in aging societies. Today there are no cures for neurological diseases and effective drug therapies are very much needed. For decades drug development programs addressing common diseases of the central nervous system (CNS) show particularly high failure rates and little progress. Clearly, clinicians and researchers require much better in vitro and in vivo models to identify and develop new, effective and safe drugs.

In recent years, advances in neurobiology helped to understand the pivotal role of soluble prion-like misfolded protein aggregates in the formation of neurodegenerative diseases. SynAging builds on these insights and has proprietary procedures to create these aggregates with highest reproducibility. Oligomers are used in vitro and in vivo to induce neurodegeneration acutely and provide drug developers with fast access to phenotypic models mimicking the corresponding neurodegenerative disease.

SynAging focuses on disease-inducing misfolded and oligomeric protein assemblies, which are involved in all stages of age-related neurodegenerative diseases.

See Science and Technology.

 

SynAging is a contract research organization (CRO) which provides:

  • Disease relevance to facilitate translation into clinical development
  • High reproducibility and reliability
  • Better results faster
  • Cost-effective services

SynAging’s services include proprietary models e.g. for Alzheimer’s Dementia (AD) and Parkinson's disease (PD) and are continuously expanded to cover other neurodegenerative indications by providing new and better models.